SCHEMBL17208620

SCHEMBL17208620

COc1c(CNc2cccc(NC(=O)c3cccc(C(F)(F)F)c3)c2)cnc2[nH]ccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DDR1 Q08345 1/20 0.55
▸ MAP3K20 Q9NYL2 6/20 0.54
▸ MAPK14 Q16539 4/20 0.54
▸ CSK P41240 3/20 0.51
▸ MAP3K7 O43318 2/20 0.49
▸ MAP4K2 Q12851 2/20 0.49
▸ EPHA2 P29317 1/20 0.49
▸ KCNK3 O14649 2/20 0.49
▸ KCNK9 Q9NPC2 1/20 0.49
▸ ESR1 P03372 1/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ MAPT P10636 1/20 0.47
▸ RXFP1 Q9HBX9 2/20 0.47
▸ BRAF P15056 1/20 0.46
▸ KCNQ3 O43525 1/20 0.46
▸ KCNQ2 O43526 1/20 0.46
▸ KCNE1 P15382 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17208706 0.97 DDR1 (0.55) DDR1MAP3K20MAPK14CSKMAP3K7
SCHEMBL17243860 0.88 KCNK3 (0.53) DDR1MAP3K20MAPK14CSKMAP3K7
SCHEMBL17208618 0.83 MAPK14 (0.76) DDR1MAP3K20MAPK14MAP3K7MAP4K2
SCHEMBL17244056 0.82 MAP3K20 (0.63) DDR1MAP3K20MAPK14CSKMAP3K7
SCHEMBL17208615 0.81 DDR1 (0.82) DDR1MAP3K20MAPK14CSKMAP3K7
SCHEMBL17208707 0.81 MAPT (0.47) DDR1KCNK3KCNK9ESR1MEN1
SCHEMBL17208613 0.81 MAP3K20 (0.81) DDR1MAP3K20MAPK14CSKMAP3K7
SCHEMBL17208650 0.79 MAPT (0.56) HTTMAPTRXFP1
SCHEMBL17208652 0.78 PIKFYVE (0.56) DDR1BRAFPIKFYVE
SCHEMBL12518523 0.77 LCK (0.64) DDR1MAP3K20MAPK14CSKHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9180127-B2 Type II Raf kinase inhibitors DANA-FARBER CANCER INSTITUTE, INC. (US) 2015-11-10 — — US disclosed
EP-2937345-A2 Type II raf kinase inhibitors Dana-Farber Cancer Institute, Inc. (US) 2015-10-28 — — EP disclosed
Send feedback